Clinical Trials Browser

Phase EARLY_PHASE1 × ibrutinib × 1 year × Clear all

NCT03295240 2025-05-13

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Phase EARLY_PHASE1 Completed

Lymphoma, Lymphoma, Mantle-Cell